The 7 most recent market catalysts affecting $SILO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 55
Silo Pharma Receives U.S. Patent Office Notice Of Allowance For Application Covering SPC-15, Its Novel Intranasal Therapeutic Targeting Post-Traumatic Stress Disorder
Silo Pharma has received a Notice of Allowance from the U.S. Patent Office for its SPC-15 therapeutic, which is designed to prevent stress-induced behavioral responses related to P…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
Silo Pharma Announces Participation In IPAC-RS 2026 Nasal Innovation Forum September 16 To 17 In Jersey City
This headline signals Silo Pharma's active engagement in the nasal drug delivery sector, a growing area within pharmaceuticals. While the immediate financial impact is limited as i…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting On August 18, 2026; Issues 165,000 Shares As Consideration For Asset Purchase
Silo Pharma's 8-K filing discloses an asset purchase agreement with Parkview Consulting, where Silo Pharma issued 165,000 shares as consideration. This event signifies a strategic …
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 65
Silo Pharma Says Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Application Covering SPC-15, Intranasal 5-HT4 Receptor Agonist Targeting PTSD And Other Stress-Induced Psychiatric Disorders
Silo Pharma has secured a Notice of Allowance for a Canadian patent covering SPC-15, an intranasal 5-HT4 receptor agonist targeting PTSD and other stress-induced psychiatric disord…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 65
Silo Pharma Says EPO Grants Patent Covering Preventative Approach Of Lead Candidate SPC-15, Intranasal, Nose-To-Brain Treatment Targeting PTSD And Stress-Induced Affective Disorders
Silo Pharma announced that the European Patent Office (EPO) granted a patent for its lead candidate, SPC-15, which is designed to prevent stress-induced psychiatric disorders like …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership
Silo Pharma's QwikAgents joining AMD's AI Developer Program provides its AI subsidiary with cloud computing credits, development tools, and training. This is significant for QwikAg…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 55
Silo Pharma's QwikAgents Accepted Into Advanced Micro Devices' AMD AI Developer Program
Silo Pharma's subsidiary, QwikAgents, gaining entry into AMD's AI Developer Program is a positive development for the company. This provides QwikAgents with access to advanced AI d…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.